- Column: UC Berkeley 'very concerned' about its own dubious marketing scheme
- Drug helped dementia patients curb their hallucinations and delusions
- Eating only during a 10-hour window improved health for those with metabolic syndrome
- Letters to the Editor: Want to reduce suicide rates? Focus on gun control and mental healthcare
- A troubled ex-USC football star died at 31. His family hoped that studying his brain for CTE would h
- COP 25: Educators firmly commit to helping address the climate emergency
- The global trade union movement puts the Philippine government on notice: hands off human and trade
- PISA results highlight pressures in education systems
- Latin America, united more than ever against neoliberalism and the extreme right
- International Day of Persons with Disabilities: EI calls for inclusion
- Biden confronted on Ukraine but doesn't answer, later links Trump to El Paso massacre
- Trump camp fumes over Google’s new political ads policy: ‘It is a removal of free speech’
- White House defends Melania Trump's public silence on president's tweet mocking Greta Thunberg
- Pennsylvania veteran who lost leg in Afghanistan running for Congress against incumbent Dem
- Sanders calls Omar ‘extraordinary’ as he teams up with ‘Squad’ member in New Hampshire
With Covered California enrollment ongoing, consumers wonder if they qualify for subsidies.
One breast cancer drug showed particular ability to reach tumors in the brain, which are notoriously tough to treat.
Supreme Court seems supportive of a $12-billion claim by insurers who say they covered high-risk patients, then were subject to a "bait-and-switch."
Better than pricing drugs according to "value" would be to have the federal government force pharmaceutical companies not to overcharge.
Experts at Stanford and the IRS found that the Obamacare mandate got people to buy insurance, and the insurance reduced death rates
The university hired a firm that mailed out a "confidential survey" designed to prompt people to purchase health-related books costing about $100.
A drug that curbs delusions in Parkinson's patients did the same for people with Alzheimer's disease and other forms of dementia. The benefit was clear.